ARIANA CAMPOS YANG
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- Reactions to Shrimp Including Severe Anaphylaxis in Mite- and Cockroach-Allergic Patients Who Have Never Eaten Shrimp: Clinical Significance of IgE Cross-Reactivity to Tropomyosins From Different Sources(2019) MARTINS, T. F.; MENDONCA, T. N.; MELO, J. M. L.; MORENO, A. S.; JANUARIO, Y. C.; DASILVA, L. L. P.; DIAS, M. M.; MEIRELES, P. R.; SANTOS, K. S.; YANG, A. C.; ARRUDA, L. K.
- Underlying IPEX syndrome in a patient with idiopathic juvenile arthritis and vitiligo(2022) MENDONCA, Leonardo Oliveira; CHUSTER, Adriana Pitchon dos Reis; DORNA, Mayra Barros; BARROS, Samar Freschi; ALVES, Janaina Baptista; GONCALVES, Victor Lucas; YANG, Ariana Campos; KALIL, Jorge; TOLEDO-BARROS, Myrthes Anna Maragna; KOKRON, Cristina MariaBackground: IPEX syndrome is an X-linked inborn error of immunity clinically characterized by the triad of: enteropathy, polyendocrinopathy and eczema. However many other clinical presentations lacking the triad above described have been reported what underpin the need of careful clinical suspicion, immunological evaluation and genetic sequencing. Case presentation: Here we report a case of a Brazilian boy with severe eczema as the first and only presentation requiring cyclosporin therapy. Progressive and cumulative symptoms of arthritis and enteropathy lead to the suspicion of an inborn error of immunity. Peripheral FOXP3 expression was normal (CD127-/CD4+/CD25+/FOXP3+-396 cells-63%) and a pathogenic mutation in FOXP3 gene (c.1150G > A; p.Ala384Thr), confirmed the diagnosis of IPEX syndrome. Conclusions: IPEX syndrome should be suspected in patients presenting with severe eczema associated or not with other autoimmune/hyper inflammatory diseases in life. Our study also reinforces that FOXP3 expression by flowcytometry seems not to be a good screening method, and genetic sequencing is mandatory even in those with high suspicion and normal peripheral FOXP3 expression.
- Relative cost-effectiveness of using an extensively hydrolyzed casein formula in managing infants with cow's milk allergy in Brazil(2016) GUEST, Julian F.; YANG, Ariana C.; OBA, Jane; RODRIGUES, Maraci; CAETANO, Rosane; POLSTER, LilianObjective: To estimate the cost-effectiveness of three alternative dietetic strategies for cow's milk allergy in Brazil: 1) using an extensively hydrolyzed casein formula (eHCF; -Nutramigen) as a first-line formula, but switching to an amino acid formula (AAF) if infants remain symptomatic; 2) using an AAF as a first-line formula and then switching to an eHCF after 4 weeks once infants are symptom-free, but switching back to an AAF if infants become symptomatic; and 3) using an AAF as a first-line formula and keeping all infants on that formula. The analysis was conducted from the perspective of the Brazilian public health care system, Sistema Unico de Saude. Methods: Decision modeling was used to estimate the probability of immunoglobulin E (IgE)-mediated and non-IgE-mediated allergic infants developing tolerance to cow's milk by 12 months from starting a formula. The models also estimated the Sistema Unico de Saude cost (at 2013/2014 prices) of managing infants over 12 months after starting a formula, as well as the relative cost-effectiveness of each of the dietetic strategies. Results: The probability of developing tolerance to cow's milk by 12 months from starting a formula was higher among infants with either IgE-mediated or non-IgE-mediated allergy who were initially fed with an eHCF, compared with those who were initially fed with an AAF. The total health care cost of initially feeding an eHCF to cow's milk allergic infants was less than that of initially feeding both IgE-mediated and non-IgE-mediated infants with an AAF. Conclusion: Within the study's limitations, using an eHCF instead of an AAF for the first-line management of newly-diagnosed infants with cow's milk allergy affords a cost-effective use of publicly funded resources, since it improves the outcome for less cost.
- A concept for integrated care pathways for atopic dermatitis-A GA2LEN ADCARE initiative(2023) ZUBERBIER, Torsten; LATIFF, Amir Abdul; AGGELIDIS, Xenofon; AUGUSTIN, Matthias; BALAN, Radu-Gheorghe; BANGERT, Christine; BECK, Lisa; BIEBER, Thomas; BERNSTEIN, Jonathan A.; COLILLA, Marta Bertolin; BERARDI, Alejandro; SERRA-BALDRICH, Esther; SIEMENS, Kristina; SMITH, Cathrine; STAUBACH, Petra; STEVANOVIC, Katarina; SU-KUCUK, Ozlem; SUSSMAN, Gordon; TAVECCHIO, Simona; MITREVSKA, Natasa Teovska; THACI, Diamant; TOUBI, Elias; TRAIDL-HOFFMANN, Claudia; TREUDLER, Regina; VADASZ, Zahava; HOFMAN, Ingrid van; VENTURA, Maria Teresa; WANG, Zhao; WERFEL, Thomas; WOLLENBERG, Andreas; YANG, Ariana; YEW, Yik Weng; ZHAO, Zuotao; ZWIENER, Ricardo; WORM, Margitta; BEDBROOK, Anna; BINDSLEV-JENSEN, Carsten; BOUSQUET, Jean; BRUIN-WELLER, Marjolein de; BRUSCKY, Dayanne; BUYUKTIRYAKI, Betul; CANONICA, Giorgio Walter; CASTRO, Carla; CHANTURIDZE, Natia; CHONG-NETO, Herberto Jose; CHU, Chia-Yu; CHULAROJANAMONTRI, Leena; CORK, Michael; CRIADO, Roberta F. J.; BARREDO, Laia Curto; CUSTOVIC, Adnan; DARSOW, Ulf; EMURLAI, Arben; PABLO, Ana de; GIACCO, Stefano Del; GIROLOMONI, Giampiero; JOVANOVA, Tanja Deleva; DELEURAN, Mette; DOULADIRIS, Nikolaos; DUARTE, Bruno; DUBAKIENE, Ruta; ELLER, Esben; ENGEL-YEGER, Batya; ENSINA, Luis Felipe; FILHO, Nelson Rosario; FLOHR, Carsten; FOMINA, Daria; FRANCUZIK, Wojciech; GALIMBERTI, Maria Laura; GIMENEZ-ARNAU, Ana M.; GODSE, Kiran; MORTZ, Charlotte Gotthard; GOTUA, Maia; HIDE, Michihiro; HOETZENECKER, Wolfram; HUNZELMANN, Nicolas; IRVINE, Alan; JACK, Carolyn; KANAVAROU, Ioanna; KATOH, Norito; KINACIYAN, Tamar; KOCATUERK, Emek; KULTHANAN, Kanokvalai; LAPEERE, Hilde; LAU, Susanne; NASTRI, Mariana Machado Forti; MAKRIS, Michael; MANSOUR, Eli; MARSLAND, Alexander; FELIX, Mara Morelo Rocha; CASTRO, Ana Paula Moschione; NETTIS, Eustachio; NICOLAS, J. F.; NOSBAUM, Audrey; ODEMYR, Mikaela; PAPAPOSTOLOU, Niki; PARISI, Claudio A. S.; PAUDEL, Sushil; PETER, Jonny; POKHAREL, Prakash; PUIG, Luis; QUINT, Tamara; RAMON, German Dario; REGATEIRO, Frederico; RICCI, Giampaolo; ROSARIO, Cristine; SACKESEN, Cansin; SCHMID-GRENDELMEIER, PeterIntroduction: The integrated care pathways for atopic dermatitis (AD-ICPs) aim to bridge the gap between existing AD treatment evidence-based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co-ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems.Methods: The GA(2)LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD-ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL(2)EN ADCARE centres.Results: The AD-ICPs outline the diagnostic procedures, possible co-morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD.Conclusion: The AD-ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD.
- Fructose biphosphate aldolase: A new cassava allergen(2023) VENTURA, Anne K. R. M.; ALVES, Safiri de P.; CASTRO, Roberta A.; ROSSINI, Bruno C.; DELAZARI, Lucilense S.; OLIVEIRA, Amanda M. de; MORETTI, Ana I. S.; CASTRO, Fabio F. M.; KALIL, Jorge; YANG, Ariana C.; SANTOS, Keity S.Background: Food allergy has considerably increased in recent years and this situation has been aggravated mainly by the consumption of more processed and complex foods, since minor or potentially allergenic foods are not required to be labeled. Manihot esculenta (cassava) is a widely consumed food in South America, Africa, and Asia and can be used in the production of flour and starch, as well as several other products. This root can cause allergic reactions with symptoms ranging from mild to severe. Methods: Thus, the aim of this study was the characterization of the immunogenic cassava proteins responsible for sensitizing patients allergic to it. Using a 2D-SDS-PAGE based proteomic approach, six proteins were identified, including Fructose Bisphosphate Aldolase (FBA). Recom-binant FBA was produced in Expi293 cells and evaluated by immunoblotting with the serum of 10 individual study subjects. Results: Our results showed six cassava IgE-reactive proteins. From those, recombinant fructose bisphosphate aldolase (FBA) showed a positivity of 80% among tested sera, proving to be a highly sensitizing protein. Conclusion: The recombinant FBA molecule obtained in this study can be important for in vivo diagnostic assays, by producing more accurate results, and for desensitization protocols, in which the use of the isolated molecule produces more precise results by avoiding secondary sensitization. Trial registration: All patients signed a consent form approved by the internal ethics committee CAPPesq, Comissao de etica para Analise de Projetos de Pesquisa do HC FMUSP (CAAE: 10420619.6.0000.0068).